# Aprea Therapeutics, Inc.: Form 8-K, filed Mar 12, 2024

- Company: [Aprea Therapeutics, Inc.](/companies/apre.md) (CIK 1781983)
- Form: 8-K
- Filed: 2024-03-12
- Accepted by EDGAR: Mar 12, 2024, 16:31 ET
- Period: 2024-03-11
- Accession: 0001104659-24-033494
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1781983/000110465924033494/tm248508d1_8k.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1781983/000110465924033494/

## Items reported

- Item 1.01: Entry into a material agreement
- Item 1.02: Termination of a material agreement
- Item 3.02: Unregistered sale of equity
- Item 7.01: Regulation FD disclosure
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1781983/000110465924033494/tm248508d1_8k.htm

Filed Mar 12, 2024.
Source: SEC EDGAR, the filing index for accession 0001104659-24-033494. Last ingested by Listed: Oct 24, 2026, 15:15 ET. No prices; not investment advice.